Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA266344)
U.S. Department of Defense (CA201127)
Mayo Clinic Center for Individualized Medicine Mayo Clinic Center for Regenerative Biotherapeutics Mayo Clinic Comprehensive Cancer Center Henry J Predolin Foundation
Article History
Received: 7 March 2023
Revised: 4 July 2023
Accepted: 17 July 2023
First Online: 25 August 2023
Competing interests
: SSK is an inventor on patents in the field of CAR immunotherapy that are licensed to Novartis (through an agreement between Mayo Clinic, University of Pennsylvania, and Novartis), Humanigen (through Mayo Clinic), Mettaforge (through Mayo Clinic), Sendero (through Mayo Clinic), and MustangBio (through Mayo Clinic). SSK receives research funding from Kite, Gilead, Juno, Celgene, Novartis, Humanigen, MorphoSys, Tolero, Sunesis, LeahLabs, and Lentigen. SSK has participated in advisory meetings of Juno, Celgene, Kite, Gilead, LeahLabs, CapstanBio, Torque, Luminary, and Humanigen. SSK has participated in data safety monitoring boards of Humanigen. The other authors declare no competing interests.